<DOC>
	<DOCNO>NCT00365105</DOCNO>
	<brief_summary>RATIONALE : Zoledronate , vitamin D calcium may prevent delay bone pain symptom cause bone metastasis . It yet know whether give zoledronate together vitamin D calcium effective without strontium 89 samarium 153 treating patient bone metastasis prostate cancer , lung cancer , breast cancer . PURPOSE : This randomized phase III trial study zoledronate , vitamin D , calcium see well work compare zoledronate , vitamin D , calcium , either strontium 89 samarium 153 prevent delay bone problem patient bone metastasis prostate cancer , lung cancer , breast cancer .</brief_summary>
	<brief_title>Zoledronate , Vitamin D , Calcium With Without Strontium 89 Samarium 153 Preventing Delaying Bone Problems Patients With Bone Metastases From Prostate Cancer , Lung Cancer , Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy zoledronate , vitamin D , calcium without strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium , term prevent delay time development malignant skeletal-related event ( SREs ) ( defined pathological bone fracture , spinal cord compression , surgery bone , radiation bone ) patient bone metastasis secondary prostate , lung , breast cancer . Secondary - Compare rate SREs 1 year patient treat regimen . - Compare overall survival patient treat regimen . - Compare quality life patient treat regimen . - Compare effect regimens pain control patient . - Evaluate resource utilization cost effectiveness regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord primary disease site ( prostate v breast v lung ) number bone metastasis ( ≤ 2 v &gt; 2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive zoledronate IV 15 minute month . Patients also receive oral vitamin D oral calcium daily . Treatment continue absence disease progression unacceptable toxicity . - Arm II : Patients receive zoledronate , vitamin D , calcium arm I . Within 6 week begin study treatment , patient also receive single dose either strontium chloride Sr 89 IV samarium Sm 153 lexidronam pentasodium IV . Quality life pain assess baseline 1 , 3 , 6 , 12 month start protocol treatment . After completion study treatment , patient follow every 6 month . PROJECTED ACCRUAL : A total 352 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm lung , breast , prostate cancer Bone metastases , meet follow criterion : Must visible bone scan perform within past 4 week No painful bone metastases unless successfully treat ( i.e. , externalbeam irradiation ) prior study entry AND patient stable pain* least 2 week treatment NOTE : *Stable pain define patient response 1 , 2 , 3 Questions 4 5 The Brief Pain Inventory ( BPI ) No untreated symptomatic brain metastases No spinal cord compression Hormone receptor status specify PATIENT CHARACTERISTICS : Zubrod performance status ( PS ) 02 ( patient primary breast prostate cancer ) OR Zubrod PS 01 ( patient primary lung cancer ) White blood cell count ( WBC ) ≥ 2,400/mm³ Absolute neutrophil count ≥ 1,800/mm³ Platelet count ≥ 60,000/mm³ Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) Creatinine &lt; 3.0 mg/dL Bilirubin &lt; 2.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled congestive heart failure within past 6 month No hypertension refractory treatment within past 6 month No symptomatic coronary artery disease within past 6 month No current , active dental problem within past 4 week , include follow : Infection teeth jawbone ( maxilla mandible ) Dental fixture trauma Prior current diagnosis osteonecrosis jaw Exposed bone mouth Slow healing dental procedures No known AIDS HIV testing require PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior oral bisphosphonate therapy ( i.e . alendronate sodium similar ) allow No prior IV bisphosphonates treatment duration &gt; 6 month At least 2 week since prior calcitonin , mithramycin , gallium nitrate At least 2 week since prior externalbeam radiotherapy At least 6 week since prior concurrent dental surgery ( e.g. , extraction implant ) No prior radioisotope therapy bone metastasis Concurrent systemic chemotherapy* hormonal therapy allow Chemotherapy and/or hormonal therapy change within 14 day prior start protocol treatment ( arm I ) No concurrent bisphosphonate NOTE : *Chemotherapy must hold 2 week least 2 week radiopharmaceutical administration ( arm II )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>pain</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>